Continuing proliferation requires regulation of cyclin D1 levels in each cell cycle phase. Growth factors stimulate high levels during G2 phase, which commits the cell to continue through G1 phase with sufficient cyclin D1 to initiate DNA synthesis. Upon entry into S phase, however, cyclin D1 levels rapidly decline. Our goal is to understand the mechanism and importance of this S-phase suppression. Here, we demonstrate that cyclin D1 levels decline during S phase due to reduced protein stability, without alterations in the rate of protein synthesis. This decline depends upon Thr 286, since mutation of this site eliminates the normal pattern of cyclin D1 suppression during S phase. As evidence that phosphorylation of Thr 286 is responsible for this decline, Thr 286 is shown to be more efficiently phosphorylated during S phase than in other cell cycle periods. Finally, high cyclin D1 levels during S phase are shown to inhibit DNA synthesis. This inhibitory activity presumably blocks the growth of cells with altered cyclin D1 expression characteristics. Abnormal stimulation of cyclin D1 might result in levels high enough to promote G1/S phase transition even in the absence of appropriate growth stimuli. In such cells, however, the levels of cyclin D1 would presumably be too high to be suppressed during S phase, resulting in the inhibition of DNA synthesis.
Introduction
Cyclin D1 plays a central role in the control of proliferation. Its expression level is controlled by the signaling environment of the cell (Matsushime et al., 1991; Sewing et al., 1993; Aktas et al., 1997) . Cyclin D1 then regulates the activity of the molecules which govern passage through the cell cycle, by associating with cyclin-dependent kinase (CDK)4/6 to form a kinase for the retinoblastoma protein (Rb). Phosphorylation blocks the growth inhibitory activity of Rb and promotes the release of the transcription factor E2F (Sherr and Roberts, 1995) . Both of these events stimulate the activity of cyclins E and A in association with CDK2 (Kelly et al., 1998; Mittnacht, 1998) , along with other molecules also involved in the initiation of and passage through S phase. During S phase, the phosphorylation of Rb is carried out by cyclin A/CDK2. For this reason, cyclin D1 is essential for entry into S phase in cells with functional Rb protein, but is not required during S phase to neutralize Rb activity.
As its levels fluctuate dramatically during serum stimulation of quiescent cells, it is generally assumed that the level of expression of cyclin D1 determines to a large extent its activity (Lukas et al., 1994) . While cyclin D1 expression is vital to the induction of cell cycle progression in quiescent cells (Baldin et al., 1993) , it is not known what role it might play in the proliferative fate of the cell thereafter. Clearly, there are mechanisms to promote the continuation and ultimately the termination of cell cycle progression; however, the nature of these mechanisms, and the potential role of cyclin D1 in these processes have been difficult to study. In an effort to determine what mechanisms are involved in the decision of a cell to continue, or to terminate proliferation, cyclin D1 expression levels in asynchronous cultures were determined (Hitomi and Stacey, 1999a) . These studies were performed upon actively cycling cells to avoid any potential complications resulting from the interruption of cell cycle progression. Rather than attempt to force all cells of a culture into a given cell cycle stage, the approach was to determine the cell cycle position of each individual cell within the actively proliferating culture, by determining DNA content and time since passing through mitosis. Once the cell cycle position of an actively cycling cell was determined, it was possible to determine the expression level of cyclin D1 following staining with a fluorescent antibody and quantitative image analysis (Hitomi and Stacey, 1999a) . In this way, the expression level of cyclin D1 through the cell cycle of actively cycling cells was accurately determined. It was found that cyclin D1 is actively regulated throughout the cell cycle, with high levels observed in G1 and G2 phases, and much lower levels in S phase (Hitomi and Stacey, 1999a; Stacey, 2003) .
Owing to its central role in regulating proliferation, this expression pattern of cyclin D1 in actively cycling cells was considered to be of critical importance in regulating active cell cycle progression. Attempts were made, therefore, to relate cyclin D1 expression in each cell cycle phase to the proliferative capacity of the cell. High cyclin D1 levels in G1 phase were shown to be necessary for entry into S phase, since anti-cyclin D1 antibody microinjected during G1 phase completely blocked the initiation of DNA synthesis (Hitomi and Stacey, 1999b) . The importance of cyclin D1 expression during G2 phase became apparent when it was found that the commitment of cycling cells to continue cell cycle progression is made in G2 phase. Thus, in a cell destined to continue proliferation, it was found that cellular Ras activity must induce cyclin D1 levels during G2 phase. If Ras activity was neutralized during G2 phase, cyclin D1 levels failed to increase and the cell entered into quiescence following mitosis (Hitomi and Stacey, 1999a) . These studies, however, provided no explanation for the suppression of cyclin D1 to low levels during S phase. The fact that this occurs in virtually all normal monolayer cultures indicates that this decline is likely to have an important role in the regulation of continuing cell cycle progression. The goal of the present study was to determine how this decline is regulated, as an indication of its role in the control of proliferation. We propose that cyclin D1 levels are suppressed during S phase to emphasize the significance of the subsequent elevation during G2 phase, which commits the cell to continued proliferation.
Results

Decline in cyclin D1 during S phase is due to lower stability
Our first goal was to establish a biochemical means to study the control of cyclin D1 expression through the cell cycle, in order to extend previous studies of fluorescent staining. This required the synchronization of cells in S phase, but in a way that retained the cyclin D1 expression characteristics of asynchronous cells. Of the several approaches tested, we found that blocking cell cycle progression during S phase with a single overnight treatment with thymidine worked best. To demonstrate this fact, the expression characteristics of cyclin D1 were assessed following release from thymidine block. At various times following thymidine removal, cells were fixed and stained with a fluorescent anti-cyclin D1 antibody, and with DAPI to stain DNA. The fluorescence intensity of each fluorochrome in each cell was quantitated following photography with a CCD camera and image analysis as in previous studies (Hitomi and Stacey, 1999a) . At 2 h following thymidine removal, most cells remained in S phase and expressed low cyclin D1 levels (Figure 1a ), while at 5 h following release, the cells had entered into G2 phase and the cyclin D1 content of the cells had increased (Figure 1b) . In cycling cells, the increase in cyclin D1 during passage from S to G2 phase is totally dependent upon cellular Ras activity. This was also shown to be the case in these synchronized cultures (data not shown). Thus, even though the cells had been blocked in cell cycle progression, they passed from S to G2 phase with predictable kinetics and displayed the expected controls over elevation in cyclin D1 levels. Our attempts to use other chemical treatments, elutriation or mitotic selection proved less useful, presumable in the latter two cases because of the adverse effects of cell detachment (Sa et al., 2002) .
To confirm cyclin D1 expression levels biochemically, duplicate thymidine-treated cultures were released from thymidine block for 2 or 5 h, and lysates analysed by Western blotting for cyclin D1. As predicted by the staining patterns, the cyclin D1 protein increased following entry into G2 phase ( Figure 1c ). Rates of cyclin D1 synthesis were also analysed following a 10 min pulse with labeled amino acids, and immunoprecipitation of cyclin D1. Western analysis of the crude lysate and of the immunoprecipitate revealed the efficiency of immunoprecipitation, from which the rate of synthesis of cyclin D1 could be determined (see Materials and methods). Despite the difference in protein levels, the rate of incorporation of label into cyclin D1 protein was equivalent in the two cultures (Figure 1c and d) .
To extend the above studies, cells were labeled with amino acids as above for varying lengths of time. Incorporation of radioactivity was similar in each culture during the first 10 min as above, but after 20 and especially after 40 min there was much more label in G2 phase cyclin D1 (Figure 1e ). This observation could indicate that while the rate of synthesis is similar, the cyclin D1 protein was more stable in the G2-phase cells, resulting in increased label accumulation. To support this, cells were treated with the proteasomal inhibitor MG132 and the cultures labeled for varying length of time. With protein degradation interrupted, the incorporation of labeled amino acids was similar in both cell cycle periods (Figure 1f ). Taken together, these results indicate that while cyclin D1 levels are high in G2 phase, their lower levels during S phase are due to decreased stability of the protein.
Decline in cyclin D1 during S phase is due to proteasomal degradation
The above studies performed in synchronized cultures raise the concern that the synchronization process might have altered the results. To address this concern, human diploid fibroblast (MRC 5) cells were treated with MG132 for various times, including a 30 min final pulse with 5-bromo-2 0 -deoxy-uridine (BrdU). The cells were fixed and stained with antibodies against BrdU, cyclin D1 and with DAPI against DNA. The fluorescence of each stain in each cell was quantitated and cyclin D1 levels plotted vs DNA, with BrdU-positive cells noted.
From fluorescence photographs of the cells treated for different times with MG132 (Figure 2a) , as well as from the plotted data (Figure 2b-d) , it is clear that the treatment with MG132 had increased cyclin D1 levels. This increase was particularly evident in S phase cells, where the typical low levels rapidly increased following drug treatment. Upon close inspection, however, it was apparent that the levels of cyclin D1 increased in all cell cycle phases following treatment with MG132. To confirm that the target of the drug was the proteasome, similar results were obtained with another proteasomal inhibitor (clasto-lactacystin b-lactone, 1.0 mM; data not shown).
To determine the extent to which cyclin D1 levels had increased in each cell cycle phase following MG132 treatment, cells in each phase were identified on the basis of DNA content and BrdU labeling. (BrdU-labeled cells were in S phase, while unlabeled cells were divided into G1 and G2 phases based upon DNA content.) The cyclin D1 levels were determined for each cell cycle phase at various times following treatment. The results indicate that cyclin D1 rapidly increased in all cell cycle phases (Figure 2e ), although this increase was slightly smaller during G2 phase in some cultures. The increased staining following proteasome inhibition serves as an approximation of the rate of cyclin D1 synthesis, and (c) Thymidine-blocked cultures were released for 2 h (S) and 5 h (G2), pulsed with labeled amino acids for 10 min, and lysed and cyclin D1 immunoprecipitated. The immunoprecipitate (cyclin D1 IP) and total lysate material (cyclin D1 Total) were subjected to Western analysis, after which the gel was autoradiographed. The immunoprecipitated band is shown in the autoradiogram. (d) S or G2 phase cultures synchronized as described above were pulsed with labeled amino acids for 10 min, and the amount of label incorporated into cyclin D1 determined (see text, Materials and methods). The numbers reported are the average of three determinations. (e) S-and G2-phase cultures were pulsed with labeled amino acids for the times noted prior to determination of the amount of label incorporated into cyclin D1. (f) Similarly, the amount of label cyclin D1 accumulating in S-and G2-phase cells were determined, except that 1 mg/ml MG132 was added during the labeling period S phase suppression of cyclin D1 Y Guo et al suggests this rate is roughly equivalent through the cell cycle. In summary, use of the proteasome inhibitor MG132 revealed that the decline in cyclin D1 during S phase is due to proteasomal degradation.
Thr 286 residue of cyclin D1 is required for the S-phase decline
To gain further information regarding the mechanism of cyclin D1 decline during S phase, a mutational analysis was performed upon the cyclin D1 protein. The average cyclin D1 levels in each cell cycle phase for each time of treatment were determined and plotted vs the time of treatment. These are typical results from single experiments that were repeated numerous times. When the average of eight experiments was determined, the increase in S phase cells was 95 (74)% that of the increase in G1-phase cells, while the increase in G2-phase cells was only 78 (77)% that of G1 phase S phase suppression of cyclin D1 Y Guo et al tolerated by the cells, since compared to the plasmid expressing wild-type cyclin D1, few stable clones expressing this protein were produced (data not shown). This is similar to observations of others (FukamiKobayashi and Mitsui, 1999) . Each of the plasmids was also introduced into cells by nuclear microinjection. To ensure that the cyclin D1 was being expressed appropriately, clones and injected plasmid concentrations (3 mg/ml wild type; 1.6 mg/ml 286 mutant) were selected to ensure that all tagged cyclin D1 was expressed exclusively in the nucleus (Figure 3a) . At this level, the amount of chimeric protein being expressed was less than the level of endogenous cyclin D1 protein (unpublished data), and had limited influence over the proliferation of the cells. It was consistently observed that when identical DNA concentrations were microinjected, the T286A cyclin D1-GFP mutant protein was expressed approximately twofold more efficiently than the wild-type cyclin D1-GFP protein.
With clones stably expressing the cyclin D1-GFP plasmid, it was possible to determine cell cycle expression characteristics of the chimeric protein with fluorescence time-lapse photography. Fluorescence photographs were taken each hour and the fluorescence intensity determined for each cell at each time point. With a clone stably expressing the wild-type construct, fluorescence intensity was high in G1 and G2 phases, and fell during S phase, as expected ( Figure 3b) . To compare the profile of expression of the wild-type and 286 mutant cyclin D1, an exhaustive study of many such profiles was obtained. As the fluorescence intensity from one cell to another varies dramatically, even within a given clone or following injection of equal concentrations of DNA, the fluorescence readings had to be carefully normalized to allow for comparison between different cells. Thus, the fluorescence of each cell was expressed as a proportion of the average expression level for that cell during the entire movie. This proportion was averaged for all cells at the same position relative to mitosis within a given movie. In this way, the relative fluorescent intensity of all cells in the culture could be obtained for each hour prior to or following mitosis. Three extensive analyses of at least 30 cells each were then averaged and the standard error of the three values for each hour determined. From this extensive analysis, it was clear that the wild-type sequence demonstrated the expected increase in cyclin D1-associated fluorescence intensity through G2 phase, followed by a decline as cells progressed through G1 and into S phase Cell cycle expression of cyclin D1: The T286A mutant and wild-type cyclin D1-GFP expression plasmids were expressed in stable clones of NIH3T3 cells and followed in fluorescence time lapse. The fluorescence of individual cells was quantitated throughout the time-lapse analysis. This fluorescence value was expressed as a proportion of the average fluorescence for each cell, and positioned relative to mitosis. In this way, the relative expression level of each protein could be determined through the cell cycle. Three analyses of at least 30 individual cells each were combined, and show that expression of the wild-type protein increases through G2 phase, and falls upon entry into S phase, while expression of the 286 mutant protein does not vary through the cell cycle. Approximate cell cycle phases are noted for each profile S phase suppression of cyclin D1 Y Guo et al however, there was no apparent alteration in fluorescence levels prior to or following mitosis ( Figure 4 ). This result indicates that the Thr at position 286 is vital for the normal fluctuations in cyclin D1 seen through the cell cycle.
To determine if another site might also be required for suppression of cyclin D1 during S phase, similar analyses were performed upon cells following nuclear microinjection of DNA. Analyses of the GFP-modified wild-type, S219G, T286A and T156A cyclin D1 mutants were performed. As above, the average fluorescence intensity of cells relative to mitosis was determined. The wild-type, T156A (Figure 5a and b) and S219G (not shown) mutants behaved similarly to one another, with an increase through G2 phase followed by a decline following G1 phase. The S219G-T286A (not shown) and the T156A-T286A (Figure 5c ) double mutants displayed no variations in fluorescence intensity through the cell cycle similar to observations with the T286A single mutant. It is important to note that the time over which cyclin D1-associated fluorescence remained high following mitosis was a reflection of the length of G1 phase in the cells being analysed. In the stable clones, G1 phase was somewhat shorter than in the microinjected cells, resulting in a shorter period of elevation in cyclin D1 levels following mitosis in stable expression clones. This fact was emphasized in human cells with a G1 phase length of nearly 10 h (U87 neuroblastoma cells), where the cyclin D1 fluorescence levels fell only after 10 h following mitosis (data not shown). We conclude that of the three sites tested, only Thr 286 is required for cell cycle regulation of cyclin D1 levels.
Phosphorylation on Thr 286 of cyclin D1 is increased during S phase
It is clear that the decline in cyclin D1 during S phase is dependent upon Thr 286, and likely that phosphorylation of Thr 286 is involved. The phosphorylation of Thr 286 leading to protein degradation has been linked to protein stability and tumor formation (Diehl et al., 1998; Alt et al., 2000) . We next, therefore, attempted to determine if phosphorylation of cyclin D1 at Thr 286 is enhanced during S phase. For these studies, we made use of a previously characterized polyclonal antibody that specifically recognized only the phosphorylated Thr 286 of cyclin D1 (see Materials and methods). NIH3T3 cells were synchronized with thymidine as above, and at various times following release from thymidine blockage lysates were collected and the amount of phospho-Thr 286 cyclin D1 were determined by Western analysis. As cyclin D1 phosphorylated at this position is likely to be rapidly degraded (Diehl et al., 1998) , we also performed these experiments following a 2 h treatment with the proteasomal inhibitor MG132. This would allow the phosphorylated protein to accumulate and be more readily detected. We found that the amount of phospho-286 cyclin D1 was greater in S-phase cells than in G2-phase cells (Figure 6a and b) , despite the fact that total cyclin D1 content was greater in the G2 phase cells. When the ratio of phospho-286 cyclin D1 to total cyclin D1 was plotted (Figure 6c) , it was clear that the proportion of phosphorylated cyclin D1 was greater in S phase cells than in G2-phase cells. This was apparent in cells treated with MG132 as well as in untreated cells (Figure 6c) .
To confirm the above results in actively cycling cells, NIH3T3 cells were fixed and stained for both phospho-286 cyclin D1 and total cyclin D1. As indicated previously, the amount of phospho-286 cyclin D1 is too low to readily detect staining in interphase cells. When the culture was treated for 2 h with MG132 to Profiles of cyclin D1-GFP mutants: Plasmid DNA expressing cyclin D1 mutants attached to the GFP sequence were microinjected into NIH3T3 cells and followed in fluorescence time lapse. Profiles of (a) wild-type cyclin D1, (b) the T156A mutant and (c) the T156A-T289A double mutant are presented. For each profile, approximately 30 individual cells were followed, quantitated and positioned relative to mitosis to allow an analysis of the variations in protein levels through the cell cycle S phase suppression of cyclin D1 Y Guo et al block degradation of the phosphorylated protein, however, the staining of individual cells became apparent. To determine the cell cycle characteristics of phosphorylation, NIH3T3 cells were treated for 2 h with MG132, fixed and stained for both phospho-286 cyclin D1 ( Figure 7a ) and for total cyclin D1 (Figure 7b ). When the ratio of these two stains was plotted vs DNA content (Figure 7c ), it was apparent that the phosphorylation of Thr 286 was greatest during S phase, and lowest during G2 phase. To further explore this observation, the average phospho-D1/total D1 fluorescence ratio was determined for all G1-and G2-phase cells. These values were then compared to this ratio at various points through S phase (Figure 7d ). At the beginning of S phase, the ratio was slightly higher than the average G1-phase ratio, but increased dramatically through mid-S phase. Near the end of S phase, the ratio declined to approach the very low average levels seen during G2 phase (Figure 7d ). These data confirm that Thr 286 is more readily phosphorylated during S phase, and supports the above contention that Thr 286 is a target of phosphorylation responsible for the lower levels of cyclin D1 during S phase.
Kinetics of cyclin D1 degradation
To confirm the possibility that altered protein stability is able to account for the decline in cyclin D1 during S phase, we compared an average profile of cyclin D1 expression to a mathematical prediction. Nine independent profiles of cyclin D1 expression through the NIH3T3 cell cycle were collected (Figure 8a ). An average profile derived from the nine typical profiles was obtained (Figure 8b ). In this profile, the average cyclin D1 level during G1 phase is set at 1.0, while the average cyclin D1 content for each DNA increment through S phase is calculated as a proportion of the G1 level. The average level for all G2-phase cells is also shown as a proportion of the average G1-phase level (Figure 8b ). For comparison to this observed profile, a mathematical prediction for cyclin D1 content through the cell cycle was made based upon several assumptions, including constant synthesis of cyclin D1 through the cell cycle. The lengths of cell cycle periods were set to typical values, and the half-life of cyclin D1 was set at 60 min during G1 and G2 phases. The half-life of cyclin D1 during S phase was set at each of the values shown, and the theoretical profile of cyclin D1 was determined by performing successive calculations through the cell cycle at 5 min intervals for each S phase half-life value (Figure 8c ). The recovery of cyclin D1 levels during G2 phase is shown, together with the average cyclin D1 level during G2 phase for each selected half-life (see Materials and methods for mathematical details). It is clear that a simple change in cyclin D1 half-life can account for a rapid and dramatic decline in cyclin D1 levels during S phase. The observed cyclin D1 profile (Figure 8b) , however, is a poor match for the theoretical profile based upon a rapid change in half-life upon entry into S phase (Figure 8c ). It appears that in NIH3T3 cells, the change in cyclin D1 half-life is gradual upon entry into S phase. This is similar to results with Thr 286 phosphorylation, where the rate of phosphorylation became maximal only when cells reached mid-S phase (Figure 7d ). The observation forms another link between Thr 286 phosphorylation and the change in cyclin D1 stability. In MRC5 cells, on the other hand (Figure 2b ), the change in half-life is apparently rapid and dramatic to account for the uniformly lower cyclin D1 levels throughout S phase. It is critical to understand not only how cyclin D1 levels decline during S phase but also why this must take place. As cyclin D1 plays such a critical role in cell cycle regulation, there is little question that this decline is important. A number of reports indicate that cyclin D1 is inhibitory to DNA synthesis Fukami-Kobayashi and Mitsui, 1999) . In order to test this possibility in actively cycling cells, we microinjected the cyclin D1-GFP expression plasmid into a variety of cell types and determined the rate at which the cells incorporated BrdU thereafter. Cells were injected with plasmid DNA expressing the 286 mutant or wild-type cyclin D1 (10 mg/ml) linked to either the GFP or the HA tags. At 5 h following injection, cells were pulsed with BrdU, fixed and stained. The expression level of exogenous cyclin D1 was determined by photographing the GFP fluorescence just prior to fixation, or by staining for HA. The ability of the exogenous cyclin D1 to inhibit DNA synthesis was determined by plotting BrdU incorporation against exogenous cyclin D1 levels.
In each case, as the exogenous cyclin D1 increased, BrdU incorporation declined ( Figure 9a , g and h). To relate directly the amount of exogenous cyclin D1 expression to endogenous cyclin D1 levels, GFP expression was plotted against total cyclin D1 levels ( Figure 9c ). In only a few cells was exogenous cyclin D1 in excess of endogenous levels. In order to directly relate average BrdU incorporation to cyclin D1 expression levels, cells were divided into separate groups and the average cyclin D1 levels calculated. The groups include: (a) uninjected cells, (b) those cells expressing exogenous cyclin D1, but whose total cyclin D1 levels remained within the range seen in uninjected cells and (c) those cells with cyclin D1 levels above normal but below twice the average endogenous cyclin D1 level (See Figure 9b and d). BrdU incorporation was reduced slightly by the low levels of exogenous cyclin D1 expression, and by almost 50% in cells with the higher exogenous cyclin D1 (Figure 9b ). BrdU incorporation varies through S phase. To understand the reduction in BrdU incorporation more completely, therefore, the cell cycle-related incorporation was determined in normal cells (Figure 9e ), and those expressing high exogenous cyclin D1 levels ( Figure 9f ). BrdU incorporation was reduced throughout S phase by the exogenous cyclin D1. Finally, to compare directly the inhibitory capacity of wild-type proteins (Figure 9g ) to the T286A mutant (H), each of these linked to the HA tag was microinjected (10 mg/ml) and the level of HA expression plotted against the BrdU incorporation level. While it has been shown that when microinjected at equal concentrations, the mutant protein is expressed at two-to threefold higher levels than the wild-type protein, the two proteins are equally inhibitory when expressed to similar levels during S phase (Figure 9g and h ).
To support of the above results, we determined the effect of exogenous cyclin D1 expression upon the overall rate of cell cycle progression. The expression vectors were microinjected into NIH3T3 cells, and the length of the cell cycle determined by time-lapse microscopy. It was shown that as the level of exogenous cyclin D1 expression increased, the rate of progression through the cell cycle decreased (manuscript in review). This result supports the above conclusions, and raises an interesting question regarding the cell lines tested above for cell cycle expression levels of the mutant and wildtype proteins (Figure 4 ). We would predict that the exogenous cyclin D1 expressed in these cell lines might be inhibitory to cell cycle progression. From the above analysis (Figure 9c) , it is clear that the expression levels in these cells were less than one-fourth endogenous levels. This would suggest that these proteins might exhibit a mild but measurable reduction in the length of the cell cycle. To test this possibility, the cell cycle length was determined in each line in comparison to a cell clone without exogenous cyclin D1 expression. As predicted, there was a 37% reduction in the rate of cell cycle progression with the wild-type protein compared to the control, while the T286A mutant displayed an 48% reduction in the rate of cell cycle progression.
Discussion
As cyclin D1 plays such a critical role in controlling cell division, a knowledge of its regulation through the cell cycle should provide a key in understanding how proliferation is controlled. Studies in asynchronous cells indicate that cyclin D1 levels are regulated differently in each cell cycle phase. Cyclin D1 levels during G2 phase are sensitively controlled by the signaling environment of the cell. These G2-phase levels are maintained through G1 phase and promote initiation of DNA synthesis (Hitomi and Stacey, 1999b) . Of critical importance in these studies is the decline in cyclin D1 levels during S phase. Previous studies showed that cyclin D1 mRNA levels and transcription are constant through the cell cycle, and that the decline during S phase is most likely due to altered stability of cyclin D1 protein (Guo et al., 2002) . These observations were extended in this study with the direct demonstration that the rate of cyclin D1 synthesis does not vary during passage from S to G2 phase. The stability of the protein, however, increases upon entry into G2 phase, and is responsible for the increased level of cyclin D1 in this cell cycle period. This conclusion was based upon Figure 8 Theoretical model of cyclin D1 expression: (a) Cycling NIH3T3 cells were fixed and stained for cyclin D1, BrdU and DNA. Cyclin D1 levels for each cell were plotted vs DNA levels, with BrdU-positive (S phase cells) noted. (b) Nine such profiles were independently obtained and averaged together to generate this average rate of decline in cyclin D1 levels through S phase, presented as a solid line (7s.e.). The average levels during G1 phase were defined as 1.0, and the average G2-phase levels presented as a large, faint bar. This observed profile can be compared to the theoretical profile (c) of cyclin D1. The theoretical profile is based upon a typical cell cycle period in NIH3T3 cells (G1 (4 h), S (8 h) and G2 (4 h)). It is calculated every 5 min based upon a constant half-life of 60 min for cyclin D1 through G1 and G2 phases, and an abrupt change to the indicated half-life upon entry into and departure from S phase. The large faint bar reflects the various G2-phase levels expected for each of the S phase halflives presented The quantitative image analysis technique has been used extensively in the past to determine cell cycle patterns of protein expression, and was used here to ensure that the synchronization procedure utilized faithfully replicated the pattern of cyclin D1 expression seen in unperturbed cells. This technique was also utilized in these studies to demonstrate that proteasomal degradation is primarily responsible for the turnover of cyclin D1 throughout the cell cycle, and that the synthesis of cyclin D1 is apparently constant in all cell cycle phases. The increased degradation during S phase is dependent upon Thr 286, apparently as a result of increased phosphorylation of this site during S phase. Finally, we demonstrated that an increase in cyclin D1 during S phase is inhibitory to the rate of DNA synthesis. Phosphorylation of Thr 286 has been reported to reduce cyclin D1 stability (Diehl et al., 1998; D'Amico et al., 2000) ; and to promote cyclin D1 transport from the nucleus, where its activity is masked and its stability reduced (D'Amico et al., 2000) . These results might be interpreted to indicate, as we propose in these studies, that the activity of cyclin D1 during S phase is normally suppressed. Mutation of Thr 286 leads to increased levels and altered binding properties of cyclin D1 during S phase (Solomon et al., 2003) , although the expression levels of cyclin D1 have also been related to the levels of p27Kip1 (Han et al., 1996; Bagui et al., 2003) (manuscript in review). Glycogen synthase kinase 3 (GSK3) is reported to be responsible for phosphorylation of Thr 286 on cyclin D1 (Diehl et al., 1998; Alt et al., 2000) . If GSK3 were responsible for the phosphorylation described during S phase, it would have interesting implications. GSK3 is active until phosphorylated. One of the kinases known to perform this inhibitory phosphorylation is AKT, the target of phosphatidylinositol-3 kinase (PI-3 kinase) (Woodgett, 2001 ). This interaction would suggest, therefore, that proliferative signaling is able to stimulate the activity of PI-3 kinase, which then stimulates AKT, which in turn places the inactivating phosphate on GSK3, resulting in cyclin D1 stabilization. In other words, if GSK3 were responsible for the suppression of cyclin D1 during S phase, we would expect to see proliferative signaling, PI-3 kinase and AKT activity, all reduced specifically during S phase, while GSK3 activity would be increased. That such a possibility might exist is supported by the fact that proliferative signaling can have different effects in different cell cycle periods. For example, microinjected oncogenic Ras protein is able to induce migration in all cell cycle phases, but it is able to induce cyclin D1 expression only during G2 phase (Sa et al., 2002) . Moreover, proliferative signaling suppresses p27Kip1 levels throughout the cell cycle, yet different pathways appear to be utilized in each cell cycle phase (Sa and Stacey, 2004) . Therefore, there is reason to believe alterations in signaling activity leading to GSK3 activation during S phase could possibly be responsible for altered cyclin D1 stability. In separate studies, however, this was found not to be the case. Neither GSK3, AKT nor PI-3 kinase activities were altered during S phase, and direct interference with GSK3 activity had little effect upon the cell cycle profile of cyclin D1 expression (manuscript in preparation).
It is also possible that Chk1 might be involved in phosphorylation of Thr 286 during S phase. This kinase is the target of ATM and ATR kinases, which are activated by DNA damage. The possibility that this might be involved in the normal regulation of cyclin D1 during S phase is substantiated by the fact that ATM and Chk1 are activated in the normal course of DNA synthesis, presumably due to activating structures in the replication complex. Further study will be required to determine if this, or a similar pathway, is involved in the suppression of cyclin D1 during normal cell cycle progression. It is also possible that the kinase responsible for phosphorylation of Thr 286 is not specifically activated during S phase. In studies with 286 mutants of cyclin D1, it was observed that the association properties of the mutant cyclin protein were altered during S phase (Scovassi et al., 1997) . It is, therefore, possible that the kinase responsible for Thr 286 phosphorylation could be active throughout the cell cycle, but that cyclin D1 would be a better substrate during S phase due to alterations in its intermolecular associations. It is clear that cyclin D1 is being actively degraded throughout the cell cycle as a consequence of proteasomal degradation. Our data indicate that phosphorylation of Thr 286 is increased during S phase, but is also observed to lesser extents in G1 and G2 phases.
While further study will be required to determine the exact mechanism, a number of reports suggest the importance of cyclin D1 reduction during S phase. The ability of cyclin D1 to bind proliferating cell nuclear antigen has been known for some time (Xiong et al., 1992; Matsuoka et al., 1994) . Pagano, Draetta and co-workers then found that high levels of cyclin D1 Figure 9 Inhibition of DNA synthesis following cyclin D1 overexpression: The 286 mutant cyclin D1-GFP expression plasmid (10 mg/ ml) was injected into the nuclei of NIH3T3 cells 5 h before a 15 min pulse of BrdU, photography of the GFP expression, fixation and staining of BrdU, total cyclin D1 and DNA. (a) The expression levels of BrdU are plotted vs GFP to demonstrate the suppression of BrdU labeling by exogenous cyclin D1. (b) Cells were divided into groups according to GFP expression levels, and the average BrdU incorporation determined and plotted (see part (d)). (c) GFP fluorescence for each cell is plotted vs the total cyclin D1 level in that cell as a means to relate GFP levels to total cyclin D1 expression level. (d) Cells from this same profile are grouped together and the average BrdU incorporation level for each group presented in part (b). As an indication of the BrdU profile in cells inhibited by high exogenous cyclin D1 expression, the BrdU level is plotted vs DNA content for (e) uninjected cells, and (f) for cells expressing high levels of cyclin D1-GFP. Finally, the inhibitory capacity of the wild-type (g) and the T286A mutant (h) cyclin D1 proteins are compared. Each of these linked to the HA sequence was microinjected into NIH3T3 cells and the BrdU incorporation level plotted vs. the HA expression level S phase suppression of cyclin D1 Y Guo et al inhibited DNA synthesis Atadja et al., 1995) , apparently due to this interaction. More recent studies have confirmed these observations biochemically (Fukami-Kobayashi and Mitsui, 1999) . The most conclusive evidence that cyclin D1 levels must decline during S phase for cell cycle progression to continue, however, is presented in this study where we conclusively demonstrate the reduction in levels during S phase. Moreover, we show that the extent of inhibition of DNA synthesis was directly related to the level of exogenous cyclin D1 expression. In related studies, we have also found that exogenous cyclin D1 expression increased the overall length of the cell cycle in NIH3T3 cells, in direct proportion of the level of exogenous cyclin D1 expressed (G Sa and DW Stacey, manuscript in review). Taken together, these results make it clear that cyclin D1 must decline during S phase for the cell to synthesize DNA without inhibition.
At first, it might appear perplexing that a molecule whose expression is so vital to ongoing cell cycle progression would need to be suppressed for an extended portion of each cell cycle. Upon further consideration, however, it is clear how this system of regulation might enforce strict controls over proliferation. We propose the following model to explain the significance of the suppression of cyclin D1 during S phase. From previous work, we know that the elevation of cyclin D1 during G2 phase is essential for the cell to continue proliferating. This critical decision to elevate cyclin D1 during G2 phase is made all the more important by the suppression of these levels during the previous cell cycle period (Figure 10a) . Thus, the suppression of cyclin D1 levels during S phase ensures that any prior effects of proliferative signaling are eliminated. The signaling decision must be made all over again for each cell cycle, and this must take place just prior to passage through mitosis (Figure 10b ). The suppression of cyclin D1 during S phase, thus, ensures a close connection between the current signaling environment and cell proliferation (Stacey, 2003) .
This pattern of cyclin D1 regulation has important implications for tumor formation. It might be possible for a mutation to increase the overall cyclin D1 expression enough that its levels would be sufficient to induce continued cell growth without proliferative signaling. This would result in unrestrained cell growth were it not for the fact that cyclin D1 levels would also presumably increase during S phase and block cell cycle progression (Figure 10c ). Support for this idea was obtained following microinjection of oncogenic Ras protein into NIH3T3 cells. While cyclin D1 levels were elevated at first during G2 phase, these levels increased in all cell cycle phases as the cell progressed through the cell cycle. In time, the levels even during S phase were elevated (Sa et al., 2002) . This suggests that, in these cells, the capacity to suppress cyclin D1 during S phase is limited. Thus, artificial elevation of cyclin D1 sufficient to induce continued proliferation in the absence of appropriate growth conditions would also most likely lead to elevated levels during S phase and growth inhibition. In a tumor, therefore, dramatic elevations in cyclin D1 levels most likely will be accompanied by a reduction in the ability of cyclin D1 to inhibit DNA synthesis. c b a Figure 10 Model for regulation of cell cycle progression by cyclin D1: These figures represent the levels of expression of cyclin D1 through the cell cycle in three different conditions. (a) In normal cell cycle progression cyclin D1 levels must be high to allow entry into S phase, but are suppressed when DNA synthesis begins. This suppression of cyclin D1 during S phase allows DNA synthesis to take place, and forces the cell to elevate cyclin D1 levels again upon entry into G2 phase if cell cycle progression is to continue. (b) If the signaling environment of the cell is not conducive for the stimulation of cyclin D1 levels during G2 phase, the cell passes through mitosis with low cyclin D1 levels and immediately enters quiescence. (c) This pattern of regulation might eliminate the potential problem resulting from the constitutive, high-level expression of cyclin D1 resulting from mutation or other alteration. If cyclin D1 levels were artificially elevated, while providing a strong positive influence for entry into S phase, the levels might be too high for suppression during S phase. This would result in blockage of DNA synthesis and interruption of cell cycle progression in the aberrant cell S phase suppression of cyclin D1 Y Guo et al
Materials and methods
Materials
NIH3T3 and MRC5 cells used in the experiments were obtained from the American Type Culture Collection. Mouse and human anti-cyclin D1 antibodies are obtained from Santa Cruz Biotechnology. Plasmid pd2EGFP-N1, the vector used to generate the GFP fusion protein with cyclin D1 and 286 mutant cyclin D1, was obtained from Clontech, and was engineered t o have a half-life in the cell of approximately 2 h. The proteasomal inhibitors MG132 and lactacystin b-lactone, and BrdU were purchased from Sigma-Aldrich. Anti-rabbit IgG (whole molecule) were purchased from Sigma. The rabbit anti-phospho 286 cyclin D1 antibody was raised against two batches of peptides representing residues 280-296 of cyclin D1, plus a carboxyl-terminal cysteinyl residue. One peptide was synthesized to be phosphorylated on the equivalent of Thr 286. The resulting antibodies was purified by ion exchange chromatography and analysed by ELISA. The antibodies were tested against purified, bacterially expressed GST-cyclin D1 fusion protein comprising the C-terminal 41 amino acids of cyclin D1. Two peptides were prepared, a wild type and a T286A mutant. The anti-phospho 286 antibody recognized only the phosphorylated wild-type peptide in ELISA, and in Western analysis recognized wild-type but not mutant cyclin D1 protein following treatment with purified GSK3b. Following immunodepletion of the phospho-cyclin D1 with this antibody, the phospho-specific band disappeared in Western analysis of total cell lysates probed with antibody recognizing the whole protein, but the wild-type protein band remained.
Cell culture
NIH3T3 mouse fibroblast cells were grown in DMEM medium supplied with 10% bovine calf serum. MRC5 human fibroblast cells were cultured in DMEM with 10% fetal calf serum. The cells used in all experiments were maintained at no more than 70% confluence. For biochemical assay, NIH3T3 cells were synchronized in S phase by culture in growth medium containing 2 mM thymidine for approximately 14 h. To release the cells from the blockage, the monolayer was washed twice with PBS (371C), then cultured with 10% bovine serum containing DMEM for the indicated periods of time. Judging by the DNA content and the incidence of mitotic figures, the culture was most enriched in G2 population around 5 h after the release.
Imaging
Digital images were collected with a cooled, monochrome camera (800 Â 1000 pixels) from Roper Scientific with Metamorph software (Universal Imaging) at 200 magnification. The processing of images has been described (Hitomi and Stacey, 1999a) . Filter systems were designed by Chroma for the indicated fluorochrome. Time-lapse images were collected with the above camera at 371C under 5% CO 2 , with one image collected every 2 min. Fluorescence time-lapse movies were taken with a cooled CCD camera, and included one fluorescence photograph of GFP expression every hour, together with phase-contrast images collected every 15-30 min. Exposure with high-intensity light for fluorescence photographs was minimized, and did not have any measurable effect upon the proliferation of illuminated cells. >1000 Ci/mmol, from Amersham). The complete DMEM medium supplemented with 10% serum was used for labeling because cyclin D1 protein expression was suppressed when methionine-and cystein-free medium was used. After labeling, the cells were harvested and lysed with lysis buffer (50 mM HEPES, pH 7.6, 200 mM NaCl, 1 mM EDTA, 0.5% NP-40, 20 mM NaF, 0.1 mM sodium orthovanadate, 10 mM betaglycerophosphate, 1 mM PMSF), and 1/1000 volume of protease inhibitor cocktail for mammalian cells (Sigma, Cat# P-8340)), on ice for 30 min with brief vortexing every 10 min. The supernatant was collected after centrifugation at 10 000 g for 20 min at 41C. The supernatant was divided into two portions: one for immunoprecipitation, and the other for direct Western blotting for normalization of immunoprecipitation (see below).
For immunoprecipitation, protein G sepharose beads (Zymed) preloaded with anti-mouse cyclin D1(clone 72-13G, Santa Cruz) was added to an aliquot of lysate (8 mg antibody/ 15 ml bead bed/sample). The mixture was incubated at 41C with constant rotation for 2 h. The beads were washed three times with lysis buffer. The precipitated proteins were released by boiling in the Laemli sample buffer for 5 min and loaded onto SDS/PAGE gel (T ¼ 12%). In order to normalize the precipitated cyclin D1 protein, the aliquoted total lysates were also subjected to SDS/PAGE. Separated proteins from both precipitates and total lysate were electrotransferred on to the same nitrocellulose membrane. After the transfer, the membrane was dried and autoradiographed for a week using a Phosphoimager screen to quantitate the radioactivity of precipitated cyclin D1. This membrane was analysed by quantitative Western blotting (Hitomi and Stacey, 1999a) for cyclin D1 and actin. The correction of the radioactivity incorporation in to cyclin D1 was as follows: normalized radioactivity of total cyclin D1 ¼ (radioactivity of D1 precipitated/ Western density of precipitated cyclin D1) Â (Western density of total cyclin D1/Western density of total actin). The first parenthesis indicates the specific activity of labeled cyclin D1 protein, and the second parenthesis is the total cyclin D1 normalized for loading. Multiplying both values cancels the variation for precipitation efficiency, total cell number and loading, and the increase in total cyclin D1 upon entry into G2 phase.
Human cyclin D1 cloning, mutation and constructs of GFP fusion protein
The coding sequence of human cyclin D1 was cloned by PCR with the primers (sense primer 5 0 -GGATGGAACACCA GCTCCTGTGC-3 0 and antisense primer 5 0 -GGATGTCCAC GTCCCGCACGTCG-3 0 ). The mutation of Thr 286 to Ala was achieved by replacing the antisense with another antisense primer as 5 0 -GGATGTCCACGTCCCGCACGTCGGTGG GTGCGC-3 0 in the PCR reaction. The fragments generated by PCR were cloned into the SmaI site of the pd2EGFP-N1 vector. The recombinant plasmids were sequenced to confirm the correct reading frame and the mutation site. The plasmids for Thr 156 Ala cyclin D1 mutants were prepared by EndoFree Maxiprep from Qiagen for the transfection.
NIH3T3 cells at 50% confluence were transfected with the above plasmids expressing cyclin D1-GFP fusion protein or mutant cyclin D1-GFP fusion protein by ExGen 500 from Fermentas Life Sciences. Nontransfected cells were selected out by treatment with 800 mg/ml of G418. GFP-positive cells were maintained in 800 mg/ml G418 in later passages. These positive cells were used from time-lapse analysis.
Immunofluorescence staining of cyclin D1 and BrdU in monolayer cells NIH3T3 at 50% confluence on coverslips were fixed with 100% methanol at room temperature for 15 min. The coverslips were washed with PBS two times and blocked with blocking buffer (1% of BSA in PBS) for 4 h. For staining and image quantitation of cyclin D1, the method was that detailed previously (Hitomi and Stacey, 1999a) . Briefly, the blocked coverslips were incubated with cyclin D1 antibody (1 : 50 dilution) at 41C overnight, followed by three washes of PBS. The secondary antibody coupled with fluorochrome (1 : 1000 dilution) was applied to coverslips at 371C for 3 h or 41C overnight. Coverslips were then washed three times with PBS. BrdU staining was performed as previously described previously (Guo et al., 2002) . The coverslips were refixed with 100% methanol followed by two washes with PBS-0.5% Tween-20 and two washes of distilled water. Treatment of 1.5 N HCl was then applied to coverslips at room temperature for 10 min followed by two washes of PBS-0.5% Tween-20 at pH 7. The coverslips were reblocked with CAS block solution (ZYMED) at room temperature for 2-4 h and followed by incubating with BrdU antibody (1 : 300 dilution) at 41C overnight. After three PBS-Tween-20 washes, coverslips were incubated with secondary antibody coupled with Cy5 in 0.3% of BSA in PBS at 41C overnight. Further three washes were required before performing DAPI staining for DNA content.
Mathematical calculations of cyclin D1 levels
It was first necessary to obtain a characteristic profile of cyclin D1 expression through S phase. Nine independent profiles of cyclin D1 expression in NIH3T3 cells were selected. BrdUpositive cells (in S phase) from each individual profile were divided into 10 groups based upon increasing DNA content. The average cyclin D1 level in each S phase group was determined and expressed as a percentage of the average level of all G1-phase cells in the profile. The results from all nine profiles were then compared to determine an average profile. The level of cyclin D1 in G2-phase cells was also determined and compared to the G1 content. This observed profile was then compared to a theoretical profile generated by a mathematical model to predict cyclin D1 levels. The model was based upon the formula for exponential decay:
final level ¼ ðoriginal levelÞð0:5Þ ðtime=halfÀlifeÞ A constant rate of cyclin D1 synthesis through the cell cycle was assumed based upon the above studies, while the half-life of cyclin D1 during G1 and G2 phases was set at 60 min based upon previous studies (Guo et al., 2002) . The half-life of cyclin D1 during S phase was then set at different levels, and the theoretical cyclin D1 profile through the entire cell cycle calculated based upon separate calculations for each 5-min period. The result was repeated for various constant rates of synthesis. We found that the overall profile was not altered by changes in the rate of synthesis after the first round of replication, while variations in the half-life during S phase resulted in dramatic alterations in the profile. The G2-phase levels are shown in the prediction, and the average G2-phase level is shown in the shaded region as a step graph (Figure 8c ). Abbreviations GSK3, glycogen synthase kinase 3; PI-3 kinase, phosphatidylinositol-3 kinase; Rb, retinoblastoma; GFP, green fluorescent protein; CDK, cyclin-dependent kinase.
